Esprit Ma

422 total citations
44 papers, 274 citations indexed

About

Esprit Ma is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Esprit Ma has authored 44 papers receiving a total of 274 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 16 papers in Oncology and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Esprit Ma's work include Acute Myeloid Leukemia Research (15 papers), Acute Lymphoblastic Leukemia research (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Esprit Ma is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Acute Lymphoblastic Leukemia research (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Esprit Ma collaborates with scholars based in United States, United Kingdom and Switzerland. Esprit Ma's co-authors include Vijayveer Bonthapally, Carla DeMuro, Patrick Lefèbvre, Marci Clark, Mei Sheng Duh, Ari Gnanasakthy, Nina Thomas, Jonathan Gravel, Annie Guérin and Liviu Niculescu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Oncologist.

In The Last Decade

Esprit Ma

40 papers receiving 267 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Esprit Ma United States	9	159	102	82	58	43	44	274
Linda Schroeder United States	6	176 1.1×	107 1.0×	37 0.5×	59 1.0×	12 0.3×	11	297
Tsuneaki Hirakawa Japan	6	98 0.6×	83 0.8×	52 0.6×	56 1.0×	71 1.7×	20	248
Richard Pilot United States	5	177 1.1×	164 1.6×	64 0.8×	101 1.7×	15 0.3×	10	368
S. Verelst Netherlands	6	261 1.6×	218 2.1×	139 1.7×	36 0.6×	29 0.7×	14	337
Diane Weber United States	7	339 2.1×	198 1.9×	202 2.5×	44 0.8×	27 0.6×	13	457
Ravnit Grewal South Africa	8	99 0.6×	60 0.6×	34 0.4×	37 0.6×	70 1.6×	19	265
Richy Agajanian United States	10	150 0.9×	145 1.4×	130 1.6×	47 0.8×	30 0.7×	32	318
Andrea Patriarca Italy	11	132 0.8×	44 0.4×	95 1.2×	15 0.3×	72 1.7×	37	314
Giambattista Bertani Italy	8	302 1.9×	70 0.7×	188 2.3×	54 0.9×	42 1.0×	20	460
Gemma Osca‐Gelis Spain	7	95 0.6×	192 1.9×	48 0.6×	54 0.9×	86 2.0×	13	337

Countries citing papers authored by Esprit Ma

Since Specialization

Citations

This map shows the geographic impact of Esprit Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esprit Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esprit Ma more than expected).

Fields of papers citing papers by Esprit Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esprit Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esprit Ma. The network helps show where Esprit Ma may publish in the future.

Co-authorship network of co-authors of Esprit Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Esprit Ma. A scholar is included among the top collaborators of Esprit Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esprit Ma. Esprit Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Esprit, Elaine Yu, Davey B. Daniel, et al.. (2025). A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment. The Oncologist. 30(5).

Vidal, Gregory A., Neha Jain, Aaron Fisher, et al.. (2024). Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer Treated in the US Community Setting. JCO Oncology Practice. 20(3). 370–377. 3 indexed citations

Stricker, Thomas, Esprit Ma, Elaine Yu, et al.. (2024). Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes. The Oncologist. 29(6). 534–542. 4 indexed citations

Matasar, Matthew J., et al.. (2024). Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States. Blood. 144(Supplement 1). 3648–3648.

Matasar, Matthew J., et al.. (2024). Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective. Blood. 144(Supplement 1). 5029–5029.

Gershon, Anda, Esprit Ma, Tao Xu, et al.. (2023). Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting. Clinical Lymphoma Myeloma & Leukemia. 23(5). e222–e231. 8 indexed citations

Vidal, Gregory A., Neha Jain, Aaron J. Fisher, et al.. (2023). Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting.. Journal of Clinical Oncology. 41(16_suppl). 6508–6508. 1 indexed citations

Vachhani, Pankit, et al.. (2023). Post‐remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre‐ versus post‐VIALE‐A real‐world experience from a predominantly US community setting. Cancer Medicine. 12(17). 17914–17923. 6 indexed citations

Stricker, Thomas, Elaine Yu, Esprit Ma, et al.. (2023). Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).. Journal of Clinical Oncology. 41(16_suppl). 6507–6507. 1 indexed citations

10.

Atrash, Shebli, Esprit Ma, Sudeep Karve, et al.. (2022). Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. Blood Cancer Journal. 12(3). 46–46. 19 indexed citations

11.

Pratz, Keith W., Jipan Xie, Lei Yin, et al.. (2022). Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective. PharmacoEconomics. 40(8). 777–790. 11 indexed citations

12.

Song, Jinlin, Cat N. Bui, Esprit Ma, et al.. (2022). Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy. Journal of Managed Care & Specialty Pharmacy. 28(9). 980–988. 1 indexed citations

13.

Vanderwalde, Ari M., Esprit Ma, Elaine Yu, et al.. (2021). NGS testing patterns in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC): OneOncology (OO) sites compared to Flatiron Health Nationwide (NAT).. Journal of Clinical Oncology. 39(28_suppl). 288–288. 3 indexed citations

14.

Donnellan, William B., et al.. (2020). Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications. Blood. 136(Supplement 1). 11–12. 4 indexed citations

15.

Galsky, Matthew D., et al.. (2019). Cisplatin Ineligibility for Patients With Metastatic Urothelial Carcinoma: A Survey of Clinical Practice Perspectives Among US Oncologists. Bladder Cancer. 5(4). 281–288. 16 indexed citations

16.

Yang, Hongbo, et al.. (2017). Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Journal of Medical Economics. 20(10). 1056–1065. 25 indexed citations

17.

Ma, Esprit, Vijayveer Bonthapally, Anita Chawla, et al.. (2016). An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices. Clinical Lymphoma Myeloma & Leukemia. 16(11). 625–636.e3. 30 indexed citations

18.

Briggs, Andrew, et al.. (2016). Assessing the impact of restricted follow-up and small sample sizes on survival estimations in prostate cancer using registry data.. Journal of Clinical Oncology. 34(7_suppl). 294–294. 1 indexed citations

19.

Knopf, Kevin, Mei Sheng Duh, Marie‐Hélène Lafeuille, et al.. (2014). Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 14(5). 380–388. 35 indexed citations

20.

Rifkin, Robert M., Clara Chen, Rahul Dhanda, et al.. (2013). Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM). Blood. 122(21). 1941–1941. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact